arrow
E

Eva Van Braeckel

Ghent University
H指数:33
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Artificial intelligence responses to bronchiectasis patients’ questions: the AIR-BE study

人工智能对支气管扩张患者问题的回应:AIR-BE研究

2026-09-170
PRE
Identification of DksA as a novel pro-inflammatory mediator of Pseudomonas aeruginosa under conditions mimicking chronic cystic fibrosis lung infection

鉴定DksA为铜绿假单胞菌在模拟囊性纤维化慢性肺部感染条件下的新型促炎介质

2026-05-120
OA
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis

Elexacaftor/Tezacaftor/Ivacaftor对囊性纤维化青少年和成人患者咳嗽频率、身体活动模式及睡眠质量的影响

2026-03-310
OAAI
Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey

早期Elexacaftor-Tezacaftor-Ivacaftor在肺功能保留的囊性纤维化成人患者中使用的决定因素:来自一项欧洲多中心调查的见解

2026-03-190
OAAI
Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)

支气管扩张和哮喘: 来自欧洲支气管扩张注册中心 (EMBARC) 的数据

2024-06-018
OAAI
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
2024-04-126
OAAI
Addressing an unmet need in the management of nontuberculous mycobacterial infections in Belgium: 1 year experience of the NTM consilium

解决比利时非结核分枝杆菌感染管理中的未满足需求: NTM consilium的1年经验

2023-10-270
PRE
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19
2023-08-238
OA